ClinicalTrials.Veeva

Menu
I

IC La Serena Research | La Serena, Chile

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Gemcitabine
Nemtabrutinib
MK-7902
Cisplatin
Nivolumab
MK-6482
Vericiguat
Bomedemstat
MK-1242-035

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 24 total trials

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in partici...

Enrolling
CLL
Small-Cell Lymphoma
Drug: Nemtabrutinib
Biological: Rituximab

Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are typ...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Bendamustine
Drug: Cyclophosphamide

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenv...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab/Quavonlimab

This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intrav...

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Drug: Pegylated filgrastim
Drug: Cisplatin

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with sel...

Enrolling
Follicular Lymphoma
Mantle Cell Lymphoma
Biological: Zilovertamab vedotin
Drug: Nemtabrutinib

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of z...

Enrolling
DLBCL
Diffuse Large B-Cell Lymphoma
Drug: Bendamustine
Biological: Zilovertamab vedotin

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve U...

Enrolling
Melanoma
Drug: ABP 206
Drug: Nivolumab

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head...

Enrolling
Recurrent or Metastatic Solid Tumors
Drug: Ifinatamab deruxtecan

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or sp...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Prednisone
Biological: Rituximab Biosimilar

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Active, not recruiting
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential th...

Enrolling
Essential Thrombocythemia
Drug: Bomedemstat
Drug: Hydroxyurea

Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive.* Metastatic means can...

Active, not recruiting
Non-Small-Cell Lung Carcinoma
Lung Neoplasms
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib

The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypo...

Enrolling
Systemic Lupus Erythematosus
Biological: MK-6194
Biological: Placebo

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after in...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metas...

Active, not recruiting
Prostate Cancer Metastatic
Drug: Dexamethasone
Drug: Hydrocortisone

Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated befor...

Enrolling
Melanoma
Drug: Lenvatinib
Biological: Vibostolimab

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Daiichi Sankyo logo
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems